Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy

Journal of Clinical Microbiology

Volumn 47, Issue 2, 2009, Pages 485-488

  Jardi, Rosendo ^a,b   Rodriguez Frias, Francisco ^a,b   Tabernero, David ^b   Homs, Maria ^b   Schaper, Melanie ^a   Esteban, Rafael ^a,b   Buti, Maria ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; LAMIVUDINE; STREPTAVIDIN; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; VIRUS DNA;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DNA EXTRACTION; GENOTYPE; HEPATITIS B VIRUS; HUMAN; HYBRIDIZATION; MOLECULAR PROBE; MUTATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRUS DETECTION; DIAGNOSTIC PROCEDURE; DRUG EFFECT; EVALUATION; GENETICS; ISOLATION AND PURIFICATION; METHODOLOGY; MISSENSE MUTATION; NUCLEIC ACID HYBRIDIZATION; SENSITIVITY AND SPECIFICITY;

HEPATITIS B VIRUS;

ANTIVIRAL AGENTS; DNA, VIRAL; GENOTYPE; GUANINE; HEPATITIS B VIRUS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION, MISSENSE; NUCLEIC ACID HYBRIDIZATION; SENSITIVITY AND SPECIFICITY;

EID: 60849091915     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01678-08     Document Type: Article

References (13)

1. Colonno, R. J., E. V. Genovesi, I. Medina, L. Lamb, S. K. Durham, M. L. Huang, L. Corey, M. Littlejohn, S. Locarnini, B. C. Tennant, B. Rose, and J. M. Clark. 2001. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J. Infect. Dis. 184:1236-1245.
2. Colonno, R. J., R. R. Rose, C. J. Baldick, S. Levine, K. Pokornowski, C. F. Yu, A. Walsh, J. Fang, M. Hsu, Ch. Mazzucco, B. Eggers, S. Zhang, M. Plym, K. Klesczewski, and D. Tenney. 2006. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 44:1656-1665.
3. Hussain, M., C. J. Zhu, E. Sablon, and A. S. F. Lok. 2003. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J. Clin. Microbiol. 41:3699-3705.
4. Jardi, R., F. Rodriguez-Frias, M. Schaper, E. Giggi, D. Tabernero, M. Homs, R. Esteban, and M. Buti. 2008. Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy. J. Hepatol. 49:695-701.
5. Jardi, R., F. Rodriguez-Frias, M. Schaper, G. Ruiz, I. Elefsiniotis, R. Esteban, and M. Buti. 2007. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment naïve patients. J. Viral Hepat. 14:835-840.
6. Kalyan, D., X. Xiong, H. Yang, C. E. Westland, C. S. Gibss, S. G. Sarafianos, and E. Arnold. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine and emitricitabine J. Virol. 75:4771-4779.
7. Osiowy, C., J. P. Villeneuve, J. Heathcote, E. Giles, and J. Borlang. 2006. Detection of the rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J. Clin. Microbiol. 44:1994-1997.
8. Pas, S. D., N. Tran, R. A. De Man, C. Burghoorn-Maas, G. Vernet, and H. G. M. Miesters. 2008. Comparison of reverse hybridization, microarray, and sequence analysis for genotyping hepatitis B virus. J. Clin. Microbiol. 46:1268-1273.
9. Rodriguez-Frias, F., R. Jardi, M. Schaper, M. Gimferrer, I. Elefsiniotis, D. Tabernero, R. Esteban, and M. Buti. 2007. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues. J. Med. Virol. 79:1671-1673.
10. Tenney, D. J., S. M. Levine, R. E. Rose, A. W. Walsh, S. P. Weinheimer, L. Plym, K. W. Pokornowski, C. F. Yu, P. Angus, A. Ayres, A. Bartholomeusz, W. Sievert, G. Thompson, N. Warner, S. Locarnini, and R. J. Colonno. 2004. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 48:3498-3507.
11. Tenney, D. J., R. E. Rose, C. J. Baldick, S. M. Levine, K. A. Pokornowski, A. W. Walsh, J. Fang, Ch. F. Yu, S. Zhang, C. E. Mazzucco, B. Eggers, M. Hsu, M. J. Plym, P. Poundstone, J. Yang, and R. J. Colonno. 2007. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. 51:902-911.
12. Villet, S., A. Ollivet, Ch. Pichoud, L. Barraud, J. P. Villeneuve, C. Trepo, and F. Zoulim. 2007. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patients. J. Hepatol. 46:531-538.
13. Zoulim, F.. 2006. Antiviral therapy of chronic hepatitis B. Antivir. Res. 71:206-215.